Clinical Trial Update: Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating RC48-ADC for efficacy and safety in metastatic castration-resistant prostate cancer is ongoing, with status currently unknow…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: UNKNOWN